Get the Stockscreener App
14.15
3.66%
+0.50
Alvotech stock is currently priced at $14.15, with a 24-hour trading volume of 248.34K.
It has seen a +3.66% increased in the last 24 hours and a +13.20% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $13.62 pivot point. If it approaches the $14.03 resistance level, significant changes may occur.
Previous Close:
$13.65
Open:
$14
24h Volume:
248.34K
Market Cap:
$3.96B
Revenue:
$91.43M
Net Income/Loss:
$-551.73M
P/E Ratio:
-7.1827
EPS:
-1.97
Net Cash Flow:
$-358.66M
1W Performance:
+7.03%
1M Performance:
+13.20%
6M Performance:
+65.50%
1Y Performance:
+52.31%
1D Range:
$14.00
$14.23
52W Range:
$6.70
$18.00
Alvotech Stock (ALVO) Company Profile
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Alvotech kynnir jákvæða niðurstöðu rannsóknar á sjúklingum sem sýnir sömu klínísku virkni líftæknilyfjahliðstæðunnar AVT05 og Simponi® (golimumab)
GlobeNewswire Inc.
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
GlobeNewswire Inc.
Alvotech hlýtur markaðsleyfi í Bandaríkjunum fyrir Selarsdi (ustekinumab-aekn) líftæknilyfjahliðstæðu við Stelara
GlobeNewswire Inc.
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
GlobeNewswire Inc.
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
GlobeNewswire Inc.
Alvotech Stock (ALVO) Financials Data
Alvotech (ALVO) Revenue 2024
ALVO reported a revenue (TTM) of $91.43 million for the quarter ending December 31, 2023, a +10.12% rise year-over-year.
Alvotech (ALVO) Net Income 2024
ALVO net income (TTM) was -$551.73 million for the quarter ending December 31, 2023, a -7.43% decrease year-over-year.
Alvotech (ALVO) Cash Flow 2024
ALVO recorded a free cash flow (TTM) of -$358.66 million for the quarter ending December 31, 2023, a +0.76% increase year-over-year.
Alvotech (ALVO) Earnings per Share 2024
ALVO earnings per share (TTM) was -$2.43 for the quarter ending December 31, 2023, a -4.25% decline year-over-year.
About Alvotech
Alvotech Holdings SA, through its subsidiaries, develops and manufactures biosimilars for global markets. The company is based in Iceland.
1.69%
1.28%
Cap:
|
Volume (24h):